Memantine
Treatment for Lewy Body Dementia
Typical Dosage: 5-20 mg daily, titrated
Effectiveness
55%
Safety Score
70%
Clinical Trials
4
Participants
1.6K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
70
DangerousModerateSafe
Treatment Details
Dosage Range
5-20 mg daily, titrated
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
50(Treat 50 patients to see 1 additional serious adverse event)
Confidence Score
70%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75
Monitoring:$750
Side Effect Mgmt:$75
Total Annual:$900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$12,857/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$3,600
Prescription Access Economics
Annual Societal Loss per Patient
$655
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$75/year
Potential OTC Price
$30/year
Estimated if OTC available
Early Treatment Benefit
+0.02 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWWARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
4 completed trials for Memantine in Lewy Body Dementia
Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies
NCT00855686COMPLETEDPHASE4
199 participants
INTERVENTIONAL
Munich, Germany
Started: Jan 1, 2007
Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)
NCT00630500COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Stavanger, Norway +3 more
Started: Feb 1, 2006
Monitoring Anti-Dementia Drugs by Serum Levels
NCT04117178COMPLETEDPHASE4
132 participants
INTERVENTIONAL
Roskilde, Denmark
Started: Feb 4, 2020
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
NCT02860338COMPLETED
900 participants
OBSERVATIONAL
Started: Jan 1, 2009